Linezolid
Linezolid, Zyvox (linezolid) is a small molecule pharmaceutical. Linezolid was first approved as Zyvox on 2000-04-18. It is used to treat bacterial infections, bacterial pneumonia, bacterial skin diseases, soft tissue infections, and staphylococcal infections amongst others in the USA. It is known to target amine oxidase [flavin-containing] A and amine oxidase [flavin-containing] B.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Linezolid, Zyvox (discontinued: Linezolid, Zyvox)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Linezolid
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | Hospira | N-206473 RX | 2015-06-18 | 1 products, RLD, RS |
| ZYVOX | Pfizer | N-021130 RX | 2000-04-18 | 1 products, RLD, RS |
| ZYVOX | Pfizer | N-021131 RX | 2000-04-18 | 2 products, RLD, RS |
| ZYVOX | Pfizer | N-021132 RX | 2000-04-18 | 1 products, RLD, RS |
Show 2 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| linezolid | ANDA | 2025-06-13 |
| linezolid for oral solution | ANDA | 2015-11-18 |
| zyvox | New Drug Application | 2024-09-25 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
Clinical
Clinical Trials
201 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infections | D007239 | EFO_0000544 | — | — | 1 | 5 | 2 | 1 | 9 |
| Pneumonia | D011014 | EFO_0003106 | J18 | — | — | 1 | 4 | 4 | 9 |
| Bacterial infections | D001424 | — | A49 | 1 | — | 4 | 1 | 1 | 7 |
| Gram-positive bacterial infections | D016908 | — | — | 1 | — | 3 | 1 | 1 | 6 |
| Communicable diseases | D003141 | — | — | — | — | 5 | 1 | — | 6 |
| Staphylococcal infections | D013203 | — | A49.01 | — | — | — | 3 | 2 | 5 |
| Methicillin-resistant staphylococcus aureus | D055624 | — | — | — | — | — | 3 | 1 | 4 |
| Ventilator-associated pneumonia | D053717 | EFO_1001865 | J95.851 | — | — | — | 2 | 1 | 3 |
| Healthcare-associated pneumonia | D000077299 | — | — | — | — | — | 1 | 2 | 3 |
| Connective tissue diseases | D003240 | EFO_1001986 | M35 | — | — | — | 1 | — | 1 |
Show 2 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sepsis | D018805 | EFO_0001420 | A41.9 | — | — | 1 | — | 1 | 2 |
| Bacteremia | D016470 | EFO_0003033 | R78.81 | — | — | 2 | — | — | 2 |
| Neutropenia | D009503 | — | D70 | — | — | 1 | — | — | 1 |
| Fever | D005334 | — | R50.9 | — | — | 1 | — | — | 1 |
| Febrile neutropenia | D064147 | — | — | — | — | 1 | — | — | 1 |
| Hyperthermia | D000084462 | — | — | — | — | 1 | — | — | 1 |
| Nervous system diseases | D009422 | — | G00-G99 | — | — | 1 | — | — | 1 |
| Optic nerve diseases | D009901 | EFO_1001330 | H47.14 | — | — | 1 | — | — | 1 |
| Cross infection | D003428 | — | — | — | — | 1 | — | — | 1 |
| Pneumococcal pneumonia | D011018 | EFO_1001474 | J13 | — | — | 1 | — | — | 1 |
Show 1 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | — | 1 | — | — | 2 | 3 |
| Neoplasms | D009369 | — | C80 | — | 2 | — | — | — | 2 |
| Streptococcal infections | D013290 | EFO_1001476 | — | — | 1 | — | — | 1 | 2 |
| Fibrosis | D005355 | — | — | — | 1 | — | — | — | 1 |
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | — | 1 | — | — | — | 1 |
| Staphylococcal skin infections | D013207 | EFO_1001849 | L00 | — | 1 | — | — | — | 1 |
| Hematologic neoplasms | D019337 | — | — | — | 1 | — | — | — | 1 |
| Sinusitis | D012852 | EFO_0007486 | J32 | — | 1 | — | — | — | 1 |
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | — | 1 | — | — | — | 1 |
| Osteoarticular tuberculosis | D014394 | EFO_0007487 | A18.0 | 1 | 1 | — | — | — | 1 |
Show 1 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 4 | — | — | — | — | 4 |
| Neurosurgical procedures | D019635 | — | — | 1 | — | — | — | — | 1 |
| Burns | D002056 | — | T30.0 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Septic shock | D012772 | — | A48.3 | — | — | — | — | 4 | 4 |
| Staphylococcus aureus | D013211 | NCBITaxon_1280 | — | — | — | — | — | 3 | 3 |
| Renal insufficiency | D051437 | — | N19 | — | — | — | — | 2 | 2 |
| Shock | D012769 | — | R57.1 | — | — | — | — | 2 | 2 |
| Inappropriate prescribing | D057970 | — | — | — | — | — | — | 1 | 1 |
| Bacterial meningitis | D016920 | EFO_1000831 | G00 | — | — | — | — | 1 | 1 |
| Prosthesis-related infections | D016459 | EFO_1001406 | — | — | — | — | — | 1 | 1 |
| Asymptomatic infections | D058345 | — | — | — | — | — | — | 1 | 1 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | — | — | 1 | 1 |
| Cerebral hemorrhage | D002543 | — | — | — | — | — | — | 1 | 1 |
Show 16 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Linezolid |
| INN | linezolid |
| Description | Linezolid is an organofluorine compound that consists of 1,3-oxazolidin-2-one bearing an N-3-fluoro-4-(morpholin-4-yl)phenyl group as well as an acetamidomethyl group at position 5. A synthetic antibacterial agent that inhibits bacterial protein synthesis by binding to a site on 23S ribosomal RNA of the 50S subunit and prevents further formation of a functional 70S initiation complex. It has a role as an antibacterial drug and a protein synthesis inhibitor. It is an oxazolidinone, a member of morpholines, an organofluorine compound and a member of acetamides. |
| Classification | Small molecule |
| Drug class | oxazolidinone antibacterials |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1 |
Identifiers
| PDB | — |
| CAS-ID | 165800-03-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL126 |
| ChEBI ID | 63607 |
| PubChem CID | 441401 |
| DrugBank | DB00601 |
| UNII ID | ISQ9I6J12J (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Zyvox – Pfizer
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Linezolid
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 28,714 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
24,452 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use